← Back to Screener
Alkermes Inc. plc (ALKS)
Price$42.80
Value ScoreD
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)36.77%
Price vs S&P 500 (4W)22.33%
VGM Score55.57
Market Capitalization$7.13B
P/E Ratio (Annual)29.52x
All Metrics
P/CF (Annual)13.70x
Book Value / Share (Quarterly)$10.52
P/TBV (Annual)2.54x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)9.90%
Cash Flow / Share (Quarterly)$1.33
Price vs S&P 500 (YTD)44.81%
Gross Margin (TTM)86.63%
Net Profit Margin (TTM)9.78%
EPS (TTM)$0.90
10-Day Avg Trading Volume2.16M
EPS Excl Extra (TTM)$0.90
Revenue Growth (5Y)7.28%
EPS (Annual)$1.43
ROI (Annual)13.28%
Gross Margin (Annual)86.69%
Net Profit Margin (5Y Avg)8.60%
Cash / Share (Quarterly)$3.07
P/E Basic Excl Extra (TTM)46.71x
Revenue Growth QoQ (YoY)28.19%
P/E Normalized (Annual)29.52x
ROA (Last FY)9.72%
Revenue Growth TTM (YoY)3.21%
EBITD / Share (TTM)$1.25
ROE (5Y Avg)9.68%
Operating Margin (TTM)12.28%
Cash Flow / Share (Annual)$2.90
P/B Ratio4.07x
P/B Ratio (Quarterly)3.36x
Net Income / Employee (Annual)$117,900
EV / Revenue (TTM)5.31x
Net Interest Coverage (TTM)-39.80x
ROA (TTM)5.39%
EPS Growth QoQ (YoY)-67.15%
EV / EBITDA (TTM)39.59x
EPS Incl Extra (Annual)$1.43
Current Ratio (Annual)3.55x
Quick Ratio (Quarterly)1.53x
3-Month Avg Trading Volume2.24M
52-Week Price Return38.06%
EV / Free Cash Flow (Annual)17.26x
P/E Incl Extra (TTM)46.71x
Revenue / Employee (TTM)$762,100
Tangible BV / Share (Quarterly)$10.98
P/S Ratio (Annual)4.83x
Asset Turnover (Annual)0.59x
52-Week High$44.57
Operating Margin (5Y Avg)10.71%
EPS Excl Extra (Annual)$1.43
CapEx CAGR (5Y)-0.86%
Tangible BV CAGR (5Y)13.73%
26-Week Price Return44.69%
Quick Ratio (Annual)3.04x
13-Week Price Return50.97%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.27x
Enterprise Value$8.29B
Revenue / Share Growth (5Y)5.98%
Asset Turnover (TTM)0.55x
Book Value / Share Growth (5Y)10.39%
Revenue / Employee (Annual)$720,000
Inventory Turnover (Annual)1.04x
Pretax Margin (Annual)19.75%
Cash / Share (Annual)$3.55
3-Month Return Std Dev50.59%
Gross Margin (5Y Avg)83.86%
Net Income / Employee (TTM)$74,500
EBITDA Interim CAGR (5Y)48.48%
ROE (Last FY)13.28%
Net Interest Coverage (Annual)0.88x
EPS Basic Excl Extra (Annual)$1.43
P/FCF (TTM)14.85x
Receivables Turnover (TTM)4.28x
EV / Free Cash Flow (TTM)37.39x
Total Debt / Equity (Quarterly)0.86x
EPS Incl Extra (TTM)$0.90
Receivables Turnover (Annual)4.08x
ROI (TTM)7.24%
P/S Ratio (TTM)4.57x
Pretax Margin (5Y Avg)11.04%
Revenue / Share (Annual)$8.75
Tangible BV / Share (Annual)$10.98
Forward P/E42.48x
Free OCF CAGR (5Y)63.91%
Price vs S&P 500 (52W)13.70%
P/E Ratio (TTM)46.71x
EPS Growth TTM (YoY)-57.21%
Year-to-Date Return52.97%
5-Day Price Return1.25%
EPS Normalized (Annual)$1.43
ROA (5Y Avg)6.76%
Net Profit Margin (Annual)16.37%
Month-to-Date Return1.45%
Cash Flow / Share (TTM)$1.73
EBITD / Share (Annual)$1.54
Operating Margin (Annual)17.21%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)27.84x
ROI (5Y Avg)9.38%
P/E Excl Extra (TTM)46.71x
LT Debt / Equity (Quarterly)0.85x
EPS Basic Excl Extra (TTM)$0.90
P/TBV (Quarterly)2.54x
P/B Ratio (Annual)2.54x
Inventory Turnover (TTM)0.80x
Pretax Margin (TTM)13.06%
Book Value / Share (Annual)$10.99
Price vs S&P 500 (13W)42.72%
Beta0.33x
P/FCF (Annual)14.85x
Revenue / Share (TTM)$9.40
ROE (TTM)8.82%
52-Week Low$25.17
vGradeD
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.40est. -0.58
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.04
4.08
4.08
4.08
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALKSAlkermes Inc. plc | D | C | B | $42.80 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Alkermes is a fully integrated biotechnology company specializing in pharmaceutical products for unmet medical needs through proprietary formulation technologies. The company develops products by partnering with third-party drug suppliers and licensees, providing integrated capabilities in research, development, manufacturing, and commercialization. Primary revenue comes from the U.S., with additional operations in Ireland and international markets.